Abz2 Bispecifics Technology enables the conversion of any existing traditional antibody into a well-expressing bispecific thereby with additional therapeutic attributes. Abzyme has developed a suite of highly stable and well-expressed modular antibodies that remain functional when fused either to N- or C-termini of an existing antibody or protein.

Cross-species modular anti-CD3 antibodies and Abz2 CD3 Bispecifics Technology are available for licensing to develop bispecific T-cell engaging antibodies or BiTE for oncology and immuno-oncology targets.

Cross-species modular anti-TfR antibodies and Abz2 TfR Bispecifics Technology are available for licensing to develop antibodies capable of overcoming the blood-brain barrier for treatment of CNS disorders.

Target-specific modular high affinity anti-Digoxigenin antibodies and Abz2 DIG Bispecifics Technology are available for licensing to develop a suite of Digoxigenin-targeting bispecific antibodies for cancer pre-targeted radio-immunotherapy.

Cross-species modular anti-Albumin antibodies and Abz2 Alb Bispecifics Technology are available for licensing to extend serum half-life of antibodies or therapeutic proteins.